It has been shown that the low expression of angiotensin-converting enzyme 2 (ACE2) is associated with tumor grade in lung cancer and that upregulation of ACE2 suppresses the progression of non-small cell lung cancer (NSCLC) [5,6]. This evidence concerns the gene ACE2 and lung carcinoma.